Targeting the liver in the metabolic syndrome: Evidence from animal models

Michele Petruzzelli, Guiseppe Lo Sasso, Piero Portincasa, Giuseppe Palasciano, Antonio Moschetta

Research output: Contribution to journalArticle

Abstract

The metabolic syndrome is an emerging global epidemic characterized by clustering of metabolic abnormalities leading to increased cardiovascular risk: glucose intolerance or type 2 diabetes, dyslipidemia, hypertension, and "central" obesity. Scientists are decoding and piecing together the molecular texture underlying the metabolic syndrome: insulin resistance and dyslipidemia stand out as central pathophysiological events. In this picture, the liver rises as the leading organ in the maintenance of metabolic fitness; it serves as the first relay station for processing dietary information, and encloses the whole biochemical machinery for both glucose and lipid storage and disposal. In addition, the liver is a target of the different endocrine molecules secreted by pancreatic β-cells and adipose tissue. Evidence collected in animal models supports the central role of the liver in the metabolic syndrome. While specific bereft of insulin sensitivity in skeletal muscle and adipose tissue fails to induce diabetes at certain extent, this is constantly the outcome in case of hepatic insulin resistance. Also, dyslipidemia is currently interpreted as the result of increased flux of free fatty acids to the liver with ensuing misbalance of lipoprotein synthesis and removal. In this review we bring together recent advances in the field of lipid sensing nuclear receptors, adipokines and other molecules responsible for metabolic fitness, and provide a putative coherent frame to conceive the pathophysiology of the metabolic syndrome.

Original languageEnglish
Pages (from-to)2199-2207
Number of pages9
JournalCurrent Pharmaceutical Design
Volume13
Issue number21
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Animal Models
Dyslipidemias
Liver
Insulin Resistance
Adipose Tissue
Lipids
Adipokines
Glucose Intolerance
Abdominal Obesity
Cytoplasmic and Nuclear Receptors
Automatic Data Processing
Nonesterified Fatty Acids
Type 2 Diabetes Mellitus
Lipoproteins
Cluster Analysis
Skeletal Muscle
Maintenance
Hypertension
Glucose
Muscles

Keywords

  • Adipokines
  • Gene therapy
  • Liver
  • Metabolic syndrome
  • Mouse models
  • Nuclear receptors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Petruzzelli, M., Lo Sasso, G., Portincasa, P., Palasciano, G., & Moschetta, A. (2007). Targeting the liver in the metabolic syndrome: Evidence from animal models. Current Pharmaceutical Design, 13(21), 2199-2207. https://doi.org/10.2174/138161207781039625

Targeting the liver in the metabolic syndrome : Evidence from animal models. / Petruzzelli, Michele; Lo Sasso, Guiseppe; Portincasa, Piero; Palasciano, Giuseppe; Moschetta, Antonio.

In: Current Pharmaceutical Design, Vol. 13, No. 21, 07.2007, p. 2199-2207.

Research output: Contribution to journalArticle

Petruzzelli, M, Lo Sasso, G, Portincasa, P, Palasciano, G & Moschetta, A 2007, 'Targeting the liver in the metabolic syndrome: Evidence from animal models', Current Pharmaceutical Design, vol. 13, no. 21, pp. 2199-2207. https://doi.org/10.2174/138161207781039625
Petruzzelli M, Lo Sasso G, Portincasa P, Palasciano G, Moschetta A. Targeting the liver in the metabolic syndrome: Evidence from animal models. Current Pharmaceutical Design. 2007 Jul;13(21):2199-2207. https://doi.org/10.2174/138161207781039625
Petruzzelli, Michele ; Lo Sasso, Guiseppe ; Portincasa, Piero ; Palasciano, Giuseppe ; Moschetta, Antonio. / Targeting the liver in the metabolic syndrome : Evidence from animal models. In: Current Pharmaceutical Design. 2007 ; Vol. 13, No. 21. pp. 2199-2207.
@article{530885e239f541239ae473d8d81af1a4,
title = "Targeting the liver in the metabolic syndrome: Evidence from animal models",
abstract = "The metabolic syndrome is an emerging global epidemic characterized by clustering of metabolic abnormalities leading to increased cardiovascular risk: glucose intolerance or type 2 diabetes, dyslipidemia, hypertension, and {"}central{"} obesity. Scientists are decoding and piecing together the molecular texture underlying the metabolic syndrome: insulin resistance and dyslipidemia stand out as central pathophysiological events. In this picture, the liver rises as the leading organ in the maintenance of metabolic fitness; it serves as the first relay station for processing dietary information, and encloses the whole biochemical machinery for both glucose and lipid storage and disposal. In addition, the liver is a target of the different endocrine molecules secreted by pancreatic β-cells and adipose tissue. Evidence collected in animal models supports the central role of the liver in the metabolic syndrome. While specific bereft of insulin sensitivity in skeletal muscle and adipose tissue fails to induce diabetes at certain extent, this is constantly the outcome in case of hepatic insulin resistance. Also, dyslipidemia is currently interpreted as the result of increased flux of free fatty acids to the liver with ensuing misbalance of lipoprotein synthesis and removal. In this review we bring together recent advances in the field of lipid sensing nuclear receptors, adipokines and other molecules responsible for metabolic fitness, and provide a putative coherent frame to conceive the pathophysiology of the metabolic syndrome.",
keywords = "Adipokines, Gene therapy, Liver, Metabolic syndrome, Mouse models, Nuclear receptors",
author = "Michele Petruzzelli and {Lo Sasso}, Guiseppe and Piero Portincasa and Giuseppe Palasciano and Antonio Moschetta",
year = "2007",
month = "7",
doi = "10.2174/138161207781039625",
language = "English",
volume = "13",
pages = "2199--2207",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "21",

}

TY - JOUR

T1 - Targeting the liver in the metabolic syndrome

T2 - Evidence from animal models

AU - Petruzzelli, Michele

AU - Lo Sasso, Guiseppe

AU - Portincasa, Piero

AU - Palasciano, Giuseppe

AU - Moschetta, Antonio

PY - 2007/7

Y1 - 2007/7

N2 - The metabolic syndrome is an emerging global epidemic characterized by clustering of metabolic abnormalities leading to increased cardiovascular risk: glucose intolerance or type 2 diabetes, dyslipidemia, hypertension, and "central" obesity. Scientists are decoding and piecing together the molecular texture underlying the metabolic syndrome: insulin resistance and dyslipidemia stand out as central pathophysiological events. In this picture, the liver rises as the leading organ in the maintenance of metabolic fitness; it serves as the first relay station for processing dietary information, and encloses the whole biochemical machinery for both glucose and lipid storage and disposal. In addition, the liver is a target of the different endocrine molecules secreted by pancreatic β-cells and adipose tissue. Evidence collected in animal models supports the central role of the liver in the metabolic syndrome. While specific bereft of insulin sensitivity in skeletal muscle and adipose tissue fails to induce diabetes at certain extent, this is constantly the outcome in case of hepatic insulin resistance. Also, dyslipidemia is currently interpreted as the result of increased flux of free fatty acids to the liver with ensuing misbalance of lipoprotein synthesis and removal. In this review we bring together recent advances in the field of lipid sensing nuclear receptors, adipokines and other molecules responsible for metabolic fitness, and provide a putative coherent frame to conceive the pathophysiology of the metabolic syndrome.

AB - The metabolic syndrome is an emerging global epidemic characterized by clustering of metabolic abnormalities leading to increased cardiovascular risk: glucose intolerance or type 2 diabetes, dyslipidemia, hypertension, and "central" obesity. Scientists are decoding and piecing together the molecular texture underlying the metabolic syndrome: insulin resistance and dyslipidemia stand out as central pathophysiological events. In this picture, the liver rises as the leading organ in the maintenance of metabolic fitness; it serves as the first relay station for processing dietary information, and encloses the whole biochemical machinery for both glucose and lipid storage and disposal. In addition, the liver is a target of the different endocrine molecules secreted by pancreatic β-cells and adipose tissue. Evidence collected in animal models supports the central role of the liver in the metabolic syndrome. While specific bereft of insulin sensitivity in skeletal muscle and adipose tissue fails to induce diabetes at certain extent, this is constantly the outcome in case of hepatic insulin resistance. Also, dyslipidemia is currently interpreted as the result of increased flux of free fatty acids to the liver with ensuing misbalance of lipoprotein synthesis and removal. In this review we bring together recent advances in the field of lipid sensing nuclear receptors, adipokines and other molecules responsible for metabolic fitness, and provide a putative coherent frame to conceive the pathophysiology of the metabolic syndrome.

KW - Adipokines

KW - Gene therapy

KW - Liver

KW - Metabolic syndrome

KW - Mouse models

KW - Nuclear receptors

UR - http://www.scopus.com/inward/record.url?scp=34447513131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447513131&partnerID=8YFLogxK

U2 - 10.2174/138161207781039625

DO - 10.2174/138161207781039625

M3 - Article

C2 - 17627553

AN - SCOPUS:34447513131

VL - 13

SP - 2199

EP - 2207

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 21

ER -